Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Cardiff, UK.
Helen Durham Centre for Neuroinflammatory Disease, Department of Neurology, University Hospital of Wales, Cardiff, UK.
Eur J Neurol. 2018 Apr;25(4):701-704. doi: 10.1111/ene.13571. Epub 2018 Feb 16.
Multiple sclerosis (MS) is most frequent in Caucasian populations. However, studies of MS in other ethnic groups may offer unique insights into genetic and environmental influences on the disease, and data on long-term outcomes in these patients is limited. In this work clinical features and time to disability milestones were investigated in ethnic minority (EM) patients with MS in a UK population and comparisons were made to a Caucasian cohort from the same region.
In all, 1949 MS patients (1866 Caucasian, 83 EM) were identified from a regional disease registry. Cox proportional hazards regression was used to analyse the time to Expanded Disability Status Scale (EDSS) 3.0, 4.0 and 6.0.
Ethnic minority patients were younger at disease onset (28.6 years vs. 32.8 years, P = 0.001), and primary progressive MS was less common (EM 4.8%, Caucasian 11.6%, P = 0.03). After correction for clinical variables, ethnicity was associated with time to EDSS 3.0 [EM: hazard ratio (HR) 1.75, P < 0.0001] and 4.0 (HR 1.46, P = 0.03), but not 6.0 (HR 1.5, P = 0.05).
Ethnic minority patients reach early levels of fixed disability more rapidly than Caucasian patients, but this effect diminishes at later stages of the disease. This has implications for clinical management of these patients.
多发性硬化症(MS)在白种人群中最为常见。然而,对其他种族的 MS 研究可能会深入了解遗传和环境对疾病的影响,并且这些患者的长期预后数据有限。在这项工作中,我们研究了英国少数民族(EM)多发性硬化症患者的临床特征和残疾里程碑的时间,并与同一地区的白种人队列进行了比较。
从一个区域疾病登记处共确定了 1949 名 MS 患者(1866 名白种人,83 名 EM)。使用 Cox 比例风险回归分析来分析扩展残疾状态量表(EDSS)3.0、4.0 和 6.0 的时间。
少数民族患者的疾病发病年龄更小(28.6 岁 vs. 32.8 岁,P=0.001),原发性进行性 MS 更少见(EM 4.8%,白种人 11.6%,P=0.03)。在纠正临床变量后,种族与 EDSS 3.0 的时间相关[EM:风险比(HR)1.75,P<0.0001]和 4.0(HR 1.46,P=0.03),但与 6.0 无关(HR 1.5,P=0.05)。
少数民族患者比白种人患者更快地达到早期固定残疾水平,但这种影响在疾病后期会减弱。这对这些患者的临床管理有影响。